Effect of Dapagliflozin on 24-hour Blood Glucose in T2DM Patients Inadequately Controlled With Either Metformin Or Insulin

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 226 participants.

Also called NCT02429258

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 226 participants (enrolled count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02429258
Other papers using this trial's data
  • Effects of Dapagliflozin on 24-Hour Glycemic Control in Patients with Type 2 Diabetes: A Randomized Controlled Trial Diabetes technology & therapeutics, 2018-11 DOI, PubMed 30222367, PMC6208164 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02429258. Randomized; triple masking; primary purpose treatment. Start 2015-05 (registry gives no type); primary completion 2015-10 (actual). Results posted on 2017-04-11.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of Dapagliflozin on 24-hour Blood Glucose in T2DM Patients Inadequately Controlled With Either Metformin Or Insulin
Condition
Type II Diabetes
Intervention (Drug)
Farxiga
Intervention (Drug)
Placebo
Intervention (Drug)
Metformin
Intervention (Drug)
Insulin
Lead sponsor
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct02429258
Content hash
6839c821526250c5c5ca08b3171108b5d71c6a489022af1b889e00d839b65840